New system of self-tensioning for long-span wooden structural floors

[Abstract] A self-tensioning system that improves the behavior of elements under bending is described, from a resistant point of view such as deformations. The system is based in a force multiplying device tied in the opposite ends of the piece. Such device is activated with the loads which are transmitted to the supports, generating an eccentric tensioning force whose value varies with the magnitude of the applied loads. That tensioning force achieves an efficient redistribution of bending stresses. Different design parameters that determine the structural behavior of π-type section floors subjected to symmetrical and asymmetrical loads have been analyzed. The effectiveness shown by the system makes it especially interesting for its use in long-span structural floors with reduced depths

Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection

Oncohematological patients show a low immune response against SARS-CoV-2, both to natural infection and after vaccination. Most studies are focused on the analysis of the humoral response; therefore, the information available about the cellular immune response is limited. In this study, we analyzed the humoral and cellular immune responses in nine individuals who received chemotherapy for their oncohematological diseases, as well as consolidation with autologous stem cell transplantation (ASCT), after being naturally infected with SARS-CoV-2. All individuals had asymptomatic or mild COVID-19 and were not vaccinated against SARS-CoV-2. These results were compared with matched healthy individuals who also had mild COVID-19. The humoral response against SARS-CoV-2 was not detected in 6 of 9 oncohematological individuals prior to ASCT. The levels of antibodies and their neutralization capacity decreased after ASCT. Conversely, an enhanced cytotoxic activity against SARS-CoV-2-infected cells was observed after chemotherapy plus ASCT, mostly based on high levels of NK, NKT, and CD8+TCRγδ+ cell populations that were able to produce IFNγ and TNFα. These results highlight the importance of performing analyses not only to evaluate the levels of IgGs against SARS-CoV-2, but also to determine the quality of the cellular immune response developed during the immune reconstitution after ASCT.This work was supported by the Coordinated Research Activities at the Centro Nacional de Microbiología (CNM, Instituto de Salud Carlos III) (COV20_00679) to promote an integrated response against SARS-CoV-2 in Spain (Spanish Ministry of Science and Innovation) that is coordinated by Dr Inmaculada Casas (WHO National Influenza Center of the CNM), the Spanish Ministry of Science and Innovation (PID2019-110275RB-I00), and AES 2021 grant from Instituto de Salud Carlos III (PI21/00877). The work of Sara Rodríguez-Mora is financed by NIH grant R01AI143567. The work of Montserrat Torres is supported by Instituto de Salud Carlos III (COV20_00679). The work of Lorena Vigón is supported by a pre-doctoral grant from Instituto de Salud Carlos III (FIS PI16CIII/00034-ISCIII-FEDER).S

Patente ES 2588016 B2 Dispositivo y procedimiento de autotensado automático para forjados y vigas

[Resumen] La invención se refiere a un dispositivo de autotensado automático para forjados y vigas, formado por un sistema de bielas articuladas dispuestas en los apoyos de la viga, que conectan la viga con un tendón de tensado dispuesto en la viga y con dichos apoyos de la viga, y unos rodillos dispuestos en los apoyos contactando la viga. Así, una carga ejercida sobre la viga se transmite a los apoyos a través de las bielas originando una fuerza de tracción en el tendón de tesado y una compresión excéntrica que se transmite a la viga por medio de los rodillos. Adicionalmente la invención se refiere al procedimiento de autotensado automático para forjados y vigas que se lleva a cabo mediante el dispositivo de autotensado

Telemedicina y asma grave en nuestro entorno: reflexiones sobre la experiencia de los profesionales y propuestas para hacerla realidad

Resumen: Este documento pretende examinar la experiencia reciente de la telemedicina (TM) en el paciente con asma grave (AG). Un comité de profesionales sanitarios que participan en el manejo del asma (neumología, alergología, enfermería respiratoria y farmacia hospitalaria) intercambiaron impresiones sobre la experiencia práctica de la TM para el manejo del AG y los medios habitualmente disponibles y se complementó con una búsqueda bibliográfica con tal de conocer el estado actual de la TM en AG. Las principales barreras detectadas han sido la falta de formación tecnológica, la falta de registro de la TM en la historia clínica, la sobrecarga asistencial o los problemas de conexión a nivel de administración. Se aportan posibles soluciones como la selección del paciente, el registro de la TM en la historia clínica, su inclusión en los objetivos asistenciales o el aumento de financiación para sistemas. Además, se aportan las principales apps y web apps para el uso por parte de los pacientes y los equipos portátiles para realización de pruebas funcionales a distancia. Como conclusión, es necesario que la teleconsulta posea la misma consideración que la visita presencial con una programación en la agenda de citaciones y una estructura tanto de la entrevista médica como de las pruebas a realizar en la consulta. Se debe promover la implantación de un sistema de videollamada, de herramientas que permitan el seguimiento tanto de la adhesión terapéutica como de la técnica inhalatoria y de la función pulmonar del paciente. Abstract: This paper aims to examine the recent experience in telemedicine (TM) management of patients with severe asthma (SA). A committee of health professionals involved in asthma management (pulmonology, allergology, respiratory nursing, and hospital pharmacy) held discussion meetings on the practical experience of TM for the management of SA and the means available complemented with a bibliographic search to know the current status of TM in SA. The main barriers detected for the implementation of TM in SA have been the lack of technological training, the lack of registration of TM in the clinical history, the care overload, or the connectivity problems at the administration level. The practical solutions are provided such as the selection of the patient suitable for TM, the registration of TM in the medical record, its inclusion in the care objectives or the increase of funding for systems. Moreover, the main App and Webapp for use by patients are provided, and the portable equipment for remote functional respiratory tests. In conclusion, it is necessary that the teleconsultation has the same entity as the face-to-face visit with a schedule in the appointment's agenda and a structure of both the medical interview and the tests to be performed in each consultation. Additionally, should be promoted the implementation of a video call system, tools that allow the monitoring of both therapeutic adherence and inhalation technique, as well as the patient's lung function

Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (n = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibody-dependent cellular cytotoxicity was impaired, direct cellular cytotoxicity was similar to healthy donors in participants with autologous-HSCT, in contrast to individuals with allogeneic–HSCT, which severely deteriorated. No significant changes were observed in the immune response before and after HSCT. During follow-up, all reported post-HSCT SARS-CoV-2 infections were mild. This data emphasizes that COVID-19 vaccination is effective, necessary, and safe for individuals with OHD and also supports the persistence of some degree of immune protection after HSCT, at least in the short term, when patients cannot yet be revaccinated

Dale ambiente a tu cole

Se desarrolla un proyecto de innovación educativa que pretende sensibilizar al alumnado hacia en el cuidado del entorno, fomentando actitudes y hábitos que conformarán posteriormente conductas de respeto y cuidado del medio ambiente de los niños y niñas de Educación Infantil y Educación Primaria. En la puesta en práctica del proyecto se parte de la observación del medio ambiente más cercano teniendo en cuenta los momentos y actuaciones en las que se llevan a cabo acciones medio ambientales como en la recogida selectiva de basuras, aprovechamiento del agua, electricidad y compostaje. Continúa el desarrollo del proyecto con la experimentación de todo aquello que han observado a través de todas las actividades propuestas, siempre basadas en el principio de motivación, aprendizaje lúdico y constructivista. Finalmente se expresa lo vivido a través de de las diferentes formas y técnicas de comunicación como plástica, música, expresión oral o lectoescritura. El proyecto parte de la ilusión y motivación que los niños y niñas otorgan a las actividades presentadas para consolidar hábitos y actitudes para que estén presentes en su futura personalidad y lograr un desarrollo sostenible del planeta. Se han desarrollado nueves líneas de actuación, una por cada mes del curso escolar: clasificación de residuos; observación y recogida de frutos del entorno; compostaje; consumo excesivo y sus consecuencias medioambientales; ahorro energético; reutilización; plantaciones; uso racional del agua; y la experiencia de nuestros mayores. La puesta en marcha del proyecto ha supuesto una amplia implicación de toda la comunidad educativa, gracias a lo cual se han obtenido buenos resultados en la ejecución y valoración del mismo a lo largo del curso escolar, mejorando los hábitos medioambientales tanto en casa como en le colegio. Los resultados alcanzados son excelentes, en un corto plazo de tiempo se ha podido comprobar el cambio de actitud de los alumnos y alumnas ante el entorno.Castilla y LeónConsejería de Educación. Dirección General de Universidades e Investigación; Monasterio de Nuestra Señora de Prado, Autovía Puente Colgante s. n.; 47071 Valladolid; +34983411881; +34983411939ES

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3–4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

Simple Summary After the recent irruption of asciminib into the therapeutic arsenal for chronic myeloid leukemia, real-life data remain scarce to determine which patients may benefit most from this drug. Data on the efficacy of the drug in real-world setting have been reported, but a detailed analysis of the toxicity profile and the influence of prior intolerance to classical tyrosine kinase inhibitors (TKIs) has not been performed. The aim of the present analysis is to study in detail the toxicity profile of asciminib as well as to describe the risk of cross-toxicity with classical TKIs. These results may help to select the patient profile with the best chance of therapeutic success with asciminib monotherapy. (1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3-4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs